Home › Post-COVID Conditions (Long COVID) › Louisiana › New Orleans
Post-COVID Conditions (Long COVID) clinical trials in New Orleans, LA
3 studies for Post-COVID Conditions (Long COVID) are looking for participants at sites in and around New Orleans (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure Development
RecruitingObservational studyHealthy volunteers welcome
- Tulane University Medical Center, New Orleans
- University Medical Center New Orleans, New Orleans
Intervention to Prevent Behavioral Health Symptoms Among Pandemic Affected Children
RecruitingHealthy volunteers welcome
- Communities in Schools Gulf South, New Orleans
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
RecruitingPhase 3
- Tulane Medical Center, New Orleans
About Post-COVID Conditions (Long COVID)
Anyone who had COVID-19 can have ongoing symptoms. Learn about post-COVID conditions (long COVID), including symptoms, diagnosis, treatments, and prevention.
More about Post-COVID Conditions (Long COVID) on MedlinePlus
Post-COVID Conditions (Long COVID) trials in other cities
- New York City, NY15 studies
- Houston, TX13 studies
- Boston, MA13 studies
- Baltimore, MD12 studies
- Chicago, IL11 studies
- Washington, DC10 studies
- San Francisco, CA8 studies
- Durham, NC8 studies
- Atlanta, GA8 studies
- San Diego, CA7 studies
- Los Angeles, CA6 studies
- Pittsburgh, PA6 studies
Other studies in New Orleans
- Cancer (all types)12 studies
- Ovarian Cancer12 studies
- Breast Cancer11 studies
- Prostate Cancer10 studies
- Endometrial Cancer9 studies
- Metastatic Cancer9 studies
- Lung Cancer9 studies
- Non-Small Cell Lung Cancer9 studies
- Cardiovascular Disease9 studies
- Obesity8 studies
- Steatotic Liver Disease8 studies
- Colorectal Cancer8 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.